創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

創薬シーズ 創薬技術

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/01/20 GEM142 Nrf2 Activator COPD and Diabetic kidney disease Oral Small molecule Phase 1 A novel Nrf2 activator. Inhibited airway inflammation to a similar degree as roflumilast in a mouse smoke exposure model. Improved urinary albumin/creatinine ratio in STZ-induced rat diabetic model (Type I) and KK-Ay mouse (Type II) and inhibited damage of the renal tissues. Synergistic effects by combination with losartan on urinary albumin/creatinine ratio were noted in KK-Ay mice. No adverse events were seen in multiple dose phase 1 study even at 1000 mg/man/day. 問合せ
20/01/16 GEM141 Esophageal implant　(See note) Pediatric esophageal atresia and other conditions that affect the esophagus Implant （auto- logous) Cell therapy IND ready Esophageal implant made by combining a novel cell therapy platform (see TGEM38) with a patient’s own cells (haematopoietic stem and precursor cells). GEM141 leverages the body’s inherent capacity to heal itself as it is a “living tube” that facilitates regeneration of esophageal tissue and triggers a positive host response resulting in a tissue-engineered neo-conduit that restores continuity of the esophagus. These implants have the potential to dramatically improve the quality of life for children and adults 問合せ
20/01/08 GEM140 Limbal stem cells Intractable limbal stem cell deficiency Implan- tation Cell therapy Clinical Establishment and production of limbus-derived epithelial cell plate manufacturing process in GMP facility with excellent economic feasibility.
Phase 1 study is currently in progress. 		問合せ
20/01/08 GEM139 Staphylococcus aureus vaccine Staphylococcus aureus infection s.c. Vaccine Preclinical The vaccine comprising antigens and toxin is being developed. The candidate antigens to block the immune-evasion pathway by MSCRAMMs and toxin of S. aureus have already been defined. 問合せ
19/12/24 GEM138 Biosimilar adalimumab Same indications as adalimumab i.v. Antibody Preclinical Purified GEM138 is highly similar to ranibizumab by SDS-PAGE. GEM138 and adalimumab show a similar response in a TNF-a ELISA assay. Plant-based technology (TGEM036) was applied for production of GEM138. 問合せ
19/12/24 GEM137 Biosimilar ranibizumab Same indications as ranibizumab intra- vetreal Antibody Preclinical Peptide mapping by Mass Spectrometry confirms amino acid sequence identity of GEM137 with ranibizumab. Purified GEM137 is highly similar to ranibizumab by SDS-PAGE. Ligand (rVEGF) biding by GEM137 demonstrated to be similar to ranibizumab by ELISA. Plant-based technology (TGEM036) was applied for production of GEM137. 問合せ
19/12/24 GEM136 Biosimilar trastuzumab Same indications as trastuzumab i.v. Antibody Preclinical GEM136 N-terminal sequences are identical to trastuzumab. Levels of contaminating proteins, profiles of breakdown products and inhibitory activity to trastuzumab on in vitro growth of hER2 positive breast cancer cell line are similar between GEM136 and trastuzumab. Plant-based technology (TGEM036) was applied for production of GEM136. 問合せ
19/12/20 GEM135 Inhibition of proteasome via novel target Multiple tumors i.v., i.p. and Oral Small molecule Preclinical Novel target different from that for all the commercially available proteasome inhibitors. Works against many cancer cell lines tested including bortezomib, cisplatin and paclitaxel resistant cell lines. Significant therapeutic window between cancer and normal cells. Favorable toxicity profile. Regressed tumor growth and prolonged survival on syngeneic and xenograft mouse models. Expected to be effective against solid tumors without off target effects and peripheral neuropathy. Two lead compounds are being developed. 問合せ
19/12/06 GEM134 Anti-CD147 antibody Hematological （AML,MM etc） and solid tumors（liver, colon, lung etc） i.v. Antibody Preclinical Fully human antibody binding to human/ cynomolgus CD147.
Has been shown to be very effective in various types of cancers in vivo xenograft mouse model.
ADCC activity mainly contributes to the anti-tumor effect. 		問合せ
19/11/29 GEM058 Increase cellular ATP and promote wound healing Diabetes foot ulcer Topical Small molecules Phase 2 completed Reducing inflammation of endothelial cells of blood vessels.
Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent.
Applicable to all kind of wound and low cost treatment 		問合せ